The GSK/NIH Ebola vaccine candidate has shown a well-tolerated safety profile and generated an immune response in healthy volunteers. Larger trials are necessary to assess whether the immune responses offer protection against Ebola infection and disease.
Case Western Reserve University researchers aim to reduce false negative results in Ebola diagnosis by developing a positive control using plant virus nanoparticles. The goal is to create a reliable test for early detection and monitoring of the virus.
Researchers investigated Ebola's deadly nature, discovering that genetic changes enable the virus to become more severe with each transmission. The study sheds light on the evolutionary goal of Ebola virus to become more lethal, informing future treatment strategies.
Researchers at LSU Health New Orleans School of Medicine have discovered a toxic fragment of an Ebola virus protein that can change membrane permeability. The Delta peptide fragment has been shown to block the virus from attaching to already-infected cells, offering potential new insights for treatment and prevention.
Researchers found a correlation between human population density and vegetation cover in Africa, increasing the risk of animal-to-human Ebola transmission. In contrast, areas with low population density saw a decrease in risk, suggesting that landscape configuration plays a role in transmission.
Researchers tracked genetic mutations in Ebola virus during the West African outbreak, identifying changes that could interfere with experimental therapeutics. The study highlights the need for drug developers to assess mutation effects on efficacy.
Scientists have identified several genetic mutations in the Ebola virus that could render sequence-based treatments ineffective. The study found 10 new mutations that may interfere with monoclonal antibody, siRNA, and PMO drugs, highlighting the need to consider genetic drift when developing potential therapeutics.
A new study found that around one in five Lassa fever cases could be caused by human-to-human transmission, with a disproportionate number of cases traced back to 'super-spreaders'. The research emphasizes the importance of understanding different modes of transmission and their impact on public health strategies.
Healthcare workers face difficulties in differentiating between obstetric emergencies and suspected Ebola cases, while limited evidence exists on asymptomatic pregnant women. The article highlights the need for continual assessment of minimising risk to healthcare workers while providing lifesaving care.
A new model developed by ecologists at the University of Georgia and Pennsylvania State University projects that the Ebola epidemic in Liberia can be largely contained by June if an 85% hospitalization rate is achieved. The model takes into account various factors such as infection location, treatment, hospital capacity, and safe buria...
A new model developed by ecologists at the University of Georgia and Pennsylvania State University predicts that the Ebola epidemic in Liberia can be largely contained by June 2015 if hospitalization rates and safe burial practices are maintained. The model, which includes factors such as location of infection and treatment, hospital c...
The year saw major advances in solar cells and treatments for Ebola, as well as efforts to label GMO products and restrict neonicotinoid use. The American Chemical Society highlighted its impact on research, policy, and industry through various initiatives.
Researchers at the University of Kansas are developing an iPhone and Android app called iChequIt that gauges Ebola risk based on social media posts and contact-tracing records. The app will provide users with a running score of their likelihood of contact with the deadly virus, but it's not meant to advise people how to live their lives.
Researchers at UC Davis aim to produce Zmapp, an Ebola cocktail of antibodies, using plant cells grown in bioreactors instead of whole plants. This could enable rapid production and increase capacity for biotech companies.
A study published in EMBO Molecular Medicine suggests that contact between humans and virus-infected bats may have originated the Ebola outbreak in West Africa. The researchers found no evidence of larger wildlife being the source of infection, expanding the range of possible Ebola virus sources to insectivorous free-tailed bats.
Researchers have identified a potential universal therapeutic target for treating multiple infections, including Ebola, by targeting the GRP78 protein. The OSU-03012 (AR-12) and FDA-approved Phosphodiesterase 5 Inhibitors combination has shown promise in preventing viral replication, killing cancer cells, and reducing antibiotic-resist...
Medical ethicists offer guidance on life-sustaining therapies for Ebola patients in developed countries, balancing risks and benefits. Former Surgeon General David Satcher discusses the importance of credibility and influence in the role, emphasizing scientific evidence-based reports.
Researchers conducted the first Ebola vaccine trial in Africa using an early-generation vaccine candidate, demonstrating safety and immunogenicity. The study found that the vaccines produced similar immune responses in African and US populations, providing proof of principle for a multivalent filovirus vaccine.
A Phase 1B clinical trial in Uganda found the experimental vaccines safe and induced immune responses in healthy volunteers. The results are encouraging, as similar immune responses were observed compared to a previous US trial.
A phase 1 trial confirms two experimental Ebola DNA vaccines are safe and stimulate a similar immune response in Ugandan adults as reported in US adults earlier this year. The vaccines generated neutralizing antibodies and T-cells against the virus proteins, providing comparable safety and immune response.
The IMF's economic policies have been shown to reduce government spending on healthcare, leading to underfunded and understaffed health systems. The researchers argue that the IMF's campaigns for decentralised healthcare systems also hinder coordinated responses to outbreaks, such as Ebola.
A Ugandan doctor contracted Ebola in Sierra Leone and was flown to Germany for aggressive treatment involving the experimental drug FX06. The doctor developed severe multi-organ failure but made a marked improvement under intensive care and drug treatment, with no Ebola virus genetic material detected after 30 days.
Researchers identified 53 existing drugs that can hinder Ebola virus entry into human cells, including cancer drugs and antibiotics. This study may lead to rapid development of treatments against Ebola infection.
Researchers found evidence of significant social clustering in the ongoing Ebola outbreak, which has implications for case reporting and public health. The analysis estimated that up to 70% of cases were not reported, significantly lower than previous estimates.
A new study recommends that men in recovery from Ebola wear condoms for at least 3 months to prevent the sexual transmission of the virus. The researchers found that the virus persisted in semen for an average of 66.6 days, highlighting the need for further research into male survivors of Ebola.
Simple screenings of organ donors can help minimize the risk of Ebola transmission through organ donation. Experts recommend excluding individuals who have recently traveled to or worked in countries where Ebola is active for a 21-day period before they can donate organs.
A study by University of Utah researchers found a unique mechanism used by the Ebola virus and other related viruses to replicate. The discovery, which was made possible through computer simulations, may lead to new targets for antiviral drugs within five to 10 years.
A new study by University of Notre Dame researchers found that the most abundant protein in the Ebola virus, VP40, mediates replication and interacts with human cell lipids. This discovery may lead to novel therapeutics for combating Ebola.
A new study by a Pitt researcher reveals that there is limited scientific data on how long the Ebola virus can survive on surfaces, in water, or in liquid droplets. This knowledge gap makes it challenging to develop effective disinfection practices to prevent the spread of the disease.
The Ebola epidemic in West Africa lacks standardized treatment guidelines, with conflicting reports on mortality rates and treatments. Experts propose a range of measures, including the development of guidelines and international cooperation to ensure quality control and transparency.
Researchers discover that most typical networks are robust to both random and deliberate attacks, contrary to previous thought. They propose a simple method to explore the mathematical space of all interesting networks with a particular node degree distribution.
Ebola survivors can donate blood, care for sick patients, and generate community-based responses. Employing trained survivors as caregivers could also provide a source of income.
Researchers from Mainz and Würzburg have developed new active substances for treating the dengue virus, showing a high effectiveness rate even at low concentrations. The new inhibitors target only dengue viruses without affecting similar Hepatitis C viruses.
A Rutgers researcher has received a $640,000 NIH grant to develop a rapid Ebola test that can be used in remote locations where the disease has spread. The test, modeled after an existing tuberculosis test, will diagnose patients quickly and accurately, reducing the need for isolation and treatment delays.
A UCLA study suggests targeting 'hot zones' in sub-Saharan Africa could significantly reduce the spread of HIV. The research found that focusing on areas with higher risk of infection would prevent 40% more new infections than traditional strategies, making it a cost-effective approach.
Ebola virus disease is a febrile illness with severe gastrointestinal symptoms that can cause profound water and electrolyte depletion leading to circulatory collapse and death. Implementing practical protocols for managing fluids and electrolytes has not been given sufficient priority, which could substantially reduce the death rate.
The National Science Foundation has awarded rapid response grants to support researchers in understanding the fundamental nature of Ebola and its impact on public safety. The grants will fund projects that explore new methods for virus detection, disinfection, and medical response, as well as research into risk assessment and behavior.
A team of researchers will assess the ability of Nanotrap technology to detect Ebola virus in saliva, offering a safer and more accurate testing method. The project aims to address the dire need for better testing methods for Ebola, using non-invasive saliva collection and highly sensitive diagnostic tests.
The authors of a Transfusion commentary argue that forgoing routine lab tests may compromise patients' health more than any reduction in the risk of transmission. Experts recommend implementing well-characterized infection prevention and control recommendations to provide a safe environment for both patients and employees.
The NIAID/GSK Ebola vaccine candidate was well-tolerated and produced immune system responses in all 20 healthy adults who received it. The vaccine induced a T-cell response, including CD8 T cells, which may play an important role in immune protection against Ebola viruses.
Researchers are deciphering the 'neural code' of information being sent by neurons to the central nervous system (CNS) to diagnose and treat infections and autoimmune diseases. This could enable timely diagnoses and interventions, reducing mortality rates and complications.
An international team of researchers identified 20 real or perceived barriers to public health data-sharing, classifying them into six categories. The team proposes creating a treaty for global data-sharing and commissioning a body to monitor and facilitate data exchange.
The G20 summit attracted a massive Twitter presence, with the US and its leaders dominating conversations. Dr Peta Mitchell's interactive map revealed over 19,000 geo-referenced tweets within Brisbane's declared zones, showcasing the event's global reach and public engagement.
Researchers discovered that a key Ebola virus protein can trigger an excessive immune response, leading to massive inflammation and increased vascular permeability. This finding suggests a potential new target for reducing the severity of Ebola disease.
UTMB professors Scott Weaver and Slobodan Paessler received national awards from the American Society of Tropical Medicine and Hygiene. They are making significant contributions to understanding and controlling tropical diseases, including Ebola, mosquito-borne illnesses, and influenza.
Researchers have developed a new method to sequence Ebola virus genomes, reducing contaminating human RNA from 80% to less than 0.5%. The approach has been proven effective in the rapid sequencing of nearly 100 patient blood samples with a turnaround time of 10 days.
Radiologists have issued a special report on radiology preparedness for handling cases of Ebola virus, outlining protocols and recommendations for healthcare administrators. The report emphasizes the importance of clear communication, proper equipment use, and specialized isolation units to prevent infection of medical personnel.
A new protocol for imaging Ebola patients has been developed to minimize risk of exposure, using portable computed radiography and thorough decontamination procedures. The step-by-step guide is published in the American Journal of Roentgenology and aims to improve physicians' ability to rapidly evaluate suspected cases.
Researchers at Scripps Research Institute have identified vulnerable sites on the surface of Ebola virus that are targeted by the antibodies in ZMapp, a drug cocktail administered to patients during the 2014 outbreak. The study provides insights into how ZMapp works and suggests strategies to improve it.
A study by Johns Hopkins Bloomberg School of Public Health researcher Timothy Roberton found that a lack of trust among community members and frontline health workers contributed to the spread of Ebola. In Guinea, villagers refused to listen to public health messages, ignoring advice on how to protect themselves from the disease.
For the first time, clinicians have successfully provided hemodialysis to a patient with Ebola virus disease, resulting in recovery of kidney function. The protocol involved careful measures to maximize safety and minimize risk of secondary transmission, demonstrating that renal replacement therapies can be provided safely.
A mathematical model predicts that around 10 of 29 people with Ebola are likely to be detected at airport screening when trying to travel from West Africa to the UK and US by the end of the year.
Researchers have designed peptides to target Ebola's N-trimer protein, allowing for universal inhibition across all known and future strains. This approach enables the selection of effective drugs that block virus entry into cells.
The Ebola pandemic serves as a stark reminder of the interconnectedness of human, animal, and environmental health. The study emphasizes the urgent need to adopt a One Health approach to detect and prevent infectious diseases, particularly in developing countries.
The article highlights the link between animal health, human health, and the environment in the emergence of infectious diseases. Key findings include the need to build capacity in developing regions and the importance of One Health approach.
The UCI team has created a new technology called Integrated Comprehensive Droplet Digital Detection (IC 3D) that can detect bacterial invaders in blood samples with unprecedented speed and accuracy. In as little as 90 minutes, IC 3D can identify bacteria at single-cell sensitivity without the need for cell culture.
A single-dose Ebola vaccine given to primates through their noses and lungs protected them against infection for at least 21 weeks. The vaccine's effectiveness could help prevent the spread of Ebola and other diseases through unintentional pricks.
A new study has identified genetic material that recognizes early stages of infection in patients with hemorrhagic fevers, such as Lassa and Marburg viruses. This discovery could lead to the development of better diagnostics and improved treatment outcomes.
Researchers have found that bats carry the bacterial species Bartonella mayotimonensis, which causes deadly human infections in the USA. Bats are ideal reservoirs for pathogenic viruses and play a vital role in natural ecosystems.
Researchers discovered that Ebola and Marburg viruses edit their genetic material by adding extra nucleotides to their RNA. This process, known as RNA editing, was previously unknown in these viruses and could lead to a better understanding of their biology and the development of new treatments.